Fibroscan at Dr. Essa Lab

Fibroscan at Dr. Essa Lab

Fibroscan, medically known as Vibration-Controlled Transient Elastography (VCTE), is a cutting-edge, non-invasive diagnostic modality used to assess liver health by measuring liver stiffness (which correlates with fibrosis) and hepatic ultrasound attenuation (which correlates with steatosis or fat accumulation). Offered at Dr. Essa Lab in Karachi, Pakistan, this advanced diagnostic technology serves as a highly reliable, painless, and rapid alternative to traditional, invasive liver biopsies. By utilizing low-frequency elastic waves and ultrasound technology, Fibroscan provides clinicians with quantitative data essential for the early detection, staging, and monitoring of various chronic liver diseases.

The technology behind Fibroscan is both elegant and highly sophisticated. The device utilizes a specialized hand-held probe that is placed on the skin surface over the right lobe of the liver. The probe generates a mild, low-frequency shear wave (50 Hz) that propagates through the liver tissue. Simultaneously, ultrasound waves are transmitted to track the propagation velocity of this shear wave. Because stiffer, scarred liver tissue propagates shear waves faster than healthy, elastic tissue, the velocity of the wave is directly proportional to liver stiffness. This stiffness is quantified in kilopascals (kPa). Concurrently, the system calculates the Controlled Attenuation Parameter (CAP), which measures the decrease in amplitude (attenuation) of the ultrasound waves as they travel through the liver. Since fat tissue dampens ultrasound signals, the CAP score—expressed in decibels per meter (dB/m)—provides an accurate, quantitative measurement of hepatic steatosis.

The clinical importance of Fibroscan cannot be overstated. Historically, evaluating liver fibrosis required a percutaneous liver biopsy, an invasive procedure carrying risks of pain, internal bleeding, pneumothorax, and sampling errors due to the small tissue volume obtained. Fibroscan overcomes these limitations by evaluating a liver volume that is approximately 100 times larger than a standard biopsy core, providing a much more representative assessment of the hepatic parenchyma. This non-invasive examination is highly valuable for patients with chronic liver conditions, allowing for serial monitoring of disease progression or treatment response without the discomfort and risks associated with repeated surgical interventions.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy and prevent physiological factors from skewing the results, patients must adhere to the following preparation guidelines prior to undergoing a Fibroscan at Dr. Essa Lab:

• Mandatory Fasting: Patients must fast for a minimum of 3 to 4 hours prior to the procedure. This includes abstaining from all food, beverages, and oral intake, except for small sips of plain water. Eating triggers an increase in splanchnic blood flow and portal vein congestion, which temporarily increases intrahepatic pressure and can artificially elevate liver stiffness measurements (LSM), leading to a false-positive or exaggerated fibrosis reading.
• Medication Compliance: Essential daily medications may be taken with small sips of water. Patients should inform the clinical team of all current medications, particularly those affecting hepatic circulation or metabolic function.
• Appropriate Attire: Patients are advised to wear loose, comfortable clothing that allows easy access to the right side of the chest and upper abdomen. Tight-fitting garments should be avoided, as the right lower rib cage must be fully exposed during the scan.
• Medical History Documentation: Patients should bring all relevant medical records, including previous liver function tests (LFTs), abdominal ultrasound reports, and history of viral hepatitis or metabolic disorders, to assist the interpreting physician.
• Contraindications Check: Inform the technician if you have an active implantable medical device (such as a cardiac pacemaker or defibrillator), if you are pregnant, or if you have active ascites (fluid accumulation in the abdomen), as these conditions may affect the feasibility or safety of the procedure.

During the Procedure

The Fibroscan procedure at Dr. Essa Lab is performed in a dedicated, comfortable diagnostic suite by a trained clinical technician or radiologist. The step-by-step process is designed to maximize patient comfort and diagnostic precision:

• Patient Positioning: The patient lies flat on their back (supine position) on the examination table. The right arm is fully extended and placed behind the head. This specific posture is critical as it expands the intercostal spaces (the spaces between the ribs) on the right side of the body, providing an unobstructed acoustic window to the right lobe of the liver.
• Application of Coupling Gel: The operator identifies the optimal scanning site, typically in the mid-axillary line within the 8th to 10th intercostal space. A water-based ultrasound coupling gel is applied to the skin over this area to facilitate the transmission of ultrasound waves.
• Probe Placement and Measurement: The operator places the Fibroscan probe (typically an M probe for standard adults or an XL probe for patients with a higher body mass index) perpendicular to the skin surface. The operator then activates the device, which delivers a series of mild, painless mechanical pulses. The patient will feel a gentle tap or vibration on the skin, but no pain or discomfort.
• Data Acquisition: The system requires a minimum of 10 valid measurements to ensure statistical reliability. The advanced software automatically filters out invalid acquisitions caused by patient movement, deep breathing, or vascular structures.
• Duration and Safety: The entire procedure is completed within 10 to 15 minutes. Because Fibroscan utilizes non-ionizing ultrasound technology and low-frequency mechanical waves, it is entirely safe, free of radiation, and carries no post-procedure side effects. Patients can immediately resume their normal daily activities, including driving and eating, immediately after the test.

When is a Fibroscan Performed?

Non-Alcoholic Fatty Liver Disease (NAFLD / MASLD)

Non-Alcoholic Fatty Liver Disease, recently reclassified as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is characterized by excessive fat accumulation in the hepatocytes of individuals who consume little to no alcohol. This condition is highly prevalent in patients with obesity, insulin resistance, and dyslipidemia. Because early-stage fatty liver is clinically silent, patients rarely present with symptoms, though some may experience mild fatigue or right upper quadrant discomfort. Physicians request a Fibroscan to quantify the severity of hepatic steatosis via the CAP score and, more importantly, to screen for the development of hepatic fibrosis (NASH), which indicates active inflammation and progressive structural damage that could lead to cirrhosis.

Chronic Viral Hepatitis (Hepatitis B and C)

Chronic infections with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) cause persistent, long-term inflammation of the liver parenchyma. Over years or decades, this chronic inflammatory state triggers the progressive deposition of extracellular matrix proteins, leading to liver fibrosis. Patients are often asymptomatic until significant liver damage has occurred. Hepatologists at Dr. Essa Lab routinely utilize Fibroscan to stage the severity of liver fibrosis in viral hepatitis patients. This staging is critical for determining the timing and urgency of antiviral therapy, monitoring the efficacy of treatment, and assessing the regression of liver scarring over time.

Alcoholic Liver Disease (ALD)

Chronic, excessive consumption of alcohol is a major cause of liver pathology, progressing from simple steatosis to alcoholic hepatitis, progressive fibrosis, and ultimately end-stage cirrhosis. Symptoms of advanced ALD include jaundice, abdominal distension, and cognitive changes. Clinicians order a Fibroscan for patients with a history of chronic alcohol abuse to objectively assess the extent of both liver fat accumulation and structural scarring. The quantitative results provide a clear clinical baseline, help monitor the recovery of liver tissue during periods of sustained sobriety, and guide prognostic assessments.

Autoimmune and Cholestatic Liver Diseases

Autoimmune and cholestatic liver disorders, including Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and Primary Sclerosing Cholangitis (PSC), involve immune-mediated destruction of liver cells or the intrahepatic and extrahepatic bile ducts. This chronic destruction leads to progressive portal and periportal fibrosis. Patients frequently present with chronic pruritus (itching), profound fatigue, and elevated alkaline phosphatase (ALP) levels. Fibroscan is performed to non-invasively monitor the progression of structural liver damage in these patients, evaluate their response to immunosuppressive or ursodeoxycholic acid (UDCA) therapies, and identify those at high risk for decompensation.

Monitoring Liver Health in Metabolic Syndrome

Metabolic syndrome—a cluster of metabolic abnormalities including abdominal obesity, type 2 diabetes mellitus, systemic hypertension, and atherogenic dyslipidemia—is a potent driver of progressive liver disease. Insulin resistance promotes hepatic lipogenesis, lipid peroxidation, and inflammatory cytokine release, accelerating the progression from simple steatosis to advanced fibrosis. Physicians frequently recommend a Fibroscan as a screening tool for diabetic and obese patients, even in the presence of normal liver enzymes, to identify subclinical liver fibrosis and guide aggressive metabolic management to prevent cardiovascular and hepatic complications.

What Does a Fibroscan Detect?

A Fibroscan performed at Dr. Essa Lab is highly sensitive and specific, capable of detecting a wide range of clinical findings, pathological changes, and structural abnormalities within the liver parenchyma, including:

• Normal Hepatic Elasticity: Identification of healthy liver tissue with stiffness values typically ranging between 2.0 and 7.0 kPa, indicating the absence of significant fibrosis (F0-F1).
• Mild Liver Fibrosis (F1): Detection of early-stage scarring, characterized by minimal connective tissue expansion, often seen in early chronic hepatitis or mild fatty liver disease.
• Moderate Liver Fibrosis (F2): Identification of significant, intermediate-stage scarring with portal-to-portal septa, indicating progressive liver injury requiring therapeutic intervention.
• Severe Liver Fibrosis (F3): Detection of advanced bridging fibrosis with numerous septa, representing a critical pre-cirrhotic state that requires close clinical monitoring and aggressive treatment.
• Hepatic Cirrhosis (F4): Identification of advanced, irreversible structural remodeling of the liver, characterized by extensive nodule formation and high stiffness values (typically >12.5 to 15 kPa depending on the etiology).
• Normal Hepatic Fat Content: A CAP score of less than 238 dB/m, indicating a healthy liver with minimal or no fat accumulation (S0).
• Mild Hepatic Steatosis (S1): Detection of early fat accumulation in the liver, with a CAP score ranging from 238 to 260 dB/m, affecting less than 33% of hepatocytes.
• Moderate Hepatic Steatosis (S2): Identification of moderate fat accumulation, with a CAP score ranging from 260 to 290 dB/m, affecting 34% to 66% of hepatocytes.
• Severe Hepatic Steatosis (S3): Detection of extensive fat accumulation, with a CAP score exceeding 290 dB/m, affecting more than 67% of hepatocytes.
• Response to Antiviral Therapy: Monitoring the regression of liver stiffness in chronic Hepatitis C patients following successful treatment with direct-acting antivirals (DAAs).
• Efficacy of Lifestyle Interventions: Tracking reductions in both CAP scores and liver stiffness in patients with NAFLD/MASLD following weight loss, dietary modifications, and exercise.
• Risk of Portal Hypertension: Assessment of patients with very high stiffness values (e.g., >20 to 25 kPa) to evaluate the risk of developing clinically significant portal hypertension and esophageal varices.
• Drug-Induced Liver Injury (DILI): Monitoring liver stiffness in patients undergoing long-term therapy with potentially hepatotoxic medications, such as methotrexate or amiodarone.
• Biliary Obstruction Effects: Detecting secondary increases in liver stiffness caused by extrahepatic biliary obstruction, which resolves following successful biliary decompression.
• Congestive Hepatopathy: Identifying elevated liver stiffness secondary to passive hepatic congestion in patients with severe right-sided heart failure.
• Post-Transplant Graft Monitoring: Evaluating the health of a transplanted liver graft to detect early signs of rejection, recurrent viral hepatitis, or biliary complications.
• Cryptogenic Cirrhosis: Assisting in the diagnostic workup of patients with unexplained liver cirrhosis where traditional serological markers are negative.
• Hemochromatosis-Induced Damage: Assessing the degree of structural liver damage in patients with hereditary hemochromatosis and iron overload.
• Wilson’s Disease Progression: Monitoring hepatic involvement and structural changes in patients with copper metabolism disorders.
• Alpha-1 Antitrypsin Deficiency: Evaluating the severity of liver fibrosis in patients with genetic alpha-1 antitrypsin deficiency.
• Non-Invasive Baseline for Clinical Trials: Providing standardized, reproducible quantitative baseline measurements for patients enrolled in clinical trials for novel hepatoprotective or anti-fibrotic therapies.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing rapid, accurate, and highly professional diagnostic reporting. Because Fibroscan is an ultrasound-based, point-of-care examination, the quantitative data (LSM and CAP scores) are generated in real-time by the device’s software during the procedure. Following the scan, a consultant radiologist or hepatologist reviews the raw data, success rate, and interquartile range (IQR) to ensure clinical validity, correlating the findings with the patient’s clinical history.

The finalized, comprehensive Fibroscan report is typically available within a few hours of the procedure. Dr. Essa Lab offers multiple convenient methods for patients to access their diagnostic reports. Patients can retrieve their secure digital reports online via the official Dr. Essa Lab web portal or mobile application using their unique patient registration credentials. Additionally, reports can be delivered directly via email or WhatsApp, and physical copies can be collected from any of the convenient Dr. Essa Lab branches across Karachi. This streamlined reporting process ensures that patients and their referring physicians receive timely results to make prompt clinical decisions.

Fibroscan Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Liver Stiffness Measurement (LSM)	2.0 to 7.0 kPa (F0 to F1: No or minimal fibrosis)	> 7.0 kPa (F2 to F4: Significant, advanced fibrosis or cirrhosis)
Controlled Attenuation Parameter (CAP)	< 238 dB/m (S0: No significant hepatic steatosis)	> 238 dB/m (S1 to S3: Mild, moderate, or severe hepatic steatosis)
Interquartile Range / Median Ratio (IQR/med)	≤ 30% (Indicates high measurement reliability and low variability)	> 30% (Indicates high variability; results must be interpreted with caution)
Measurement Success Rate	≥ 60% success rate with at least 10 valid acquisitions	< 60% success rate (Unreliable scan, often due to obesity or ascites)
Right Lobe Parenchyma	Homogeneous tissue allowing uniform elastic wave propagation	Heterogeneous tissue causing rapid wave attenuation or high shear wave velocity
Acoustic Window Access	Clear, unobstructed intercostal window with minimal subcutaneous fat interference	Obstructed acoustic window due to severe thoracic obesity or narrow intercostal spaces
Peritoneal Cavity (Ascites Check)	No free fluid detected; allows proper propagation of shear waves	Presence of ascites (free fluid), which completely blocks shear wave propagation

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Fibroscan?

• Experienced Healthcare Professionals: Dr. Essa Lab features a team of highly qualified, experienced radiologists, pathologists, and clinical technicians dedicated to delivering precise diagnostic services.
• Patient-Focused Care: The organization prioritizes patient comfort, safety, and dignity throughout the diagnostic journey, ensuring a compassionate and reassuring environment.
• Quality Diagnostic Services: Operating under strict international quality control standards, Dr. Essa Lab is widely recognized for its diagnostic accuracy and reliability in Pakistan.
• Professional Reporting: All Fibroscan reports are meticulously reviewed and signed by consultant specialists, providing detailed quantitative data and clinical correlations.
• Modern Diagnostic Approach: Utilizing state-of-the-art Vibration-Controlled Transient Elastography (VCTE) technology, the lab ensures patients receive the most advanced care available.
• Comfortable Environment: The diagnostic suites are designed to be clean, modern, and comfortable, minimizing patient anxiety during the quick procedure.
• Convenient Locations: With an extensive network of branches across Karachi, patients can easily access diagnostic services close to their homes or workplaces.
• Commitment to Accurate Diagnosis: Founded on decades of clinical trust, Dr. Essa Lab remains dedicated to providing precise, evidence-based diagnostic insights to support effective patient management.